File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma

TitleAnti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma
Authors
Keywordsanti-angiogenic
fibulin-2
methylation
nasopharyngeal carcinoma
tumor suppressor
VEGF
Issue Date2012
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/onc
Citation
Oncogene, 2012, v. 31 n. 6, p. 728-738 How to Cite?
AbstractFibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/134395
ISSN
2014 Impact Factor: 8.459
2014 SCImago Journal Rankings: 3.643
ISI Accession Number ID
Funding AgencyGrant Number
University Grants CouncilAoE/M-06/08
Swedish Cancer Society
Swedish Research Council
Swedish Institute
Karolinska Institute
Funding Information:

This work was supported by University Grants Council Area of Excellence grant AoE/M-06/08 to MLL and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute, and Karolinska Institute to ERZ.

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorLaw, EWLen_HK
dc.contributor.authorCheung, AKLen_HK
dc.contributor.authorKashuba, VIen_HK
dc.contributor.authorPavlova, TVen_HK
dc.contributor.authorZabarovsky, ERen_HK
dc.contributor.authorLung, HLen_HK
dc.contributor.authorCheng, Yen_HK
dc.contributor.authorChua, Den_HK
dc.contributor.authorLaiWan Kwong, Den_HK
dc.contributor.authorTsao, SWen_HK
dc.contributor.authorSasaki, Ten_HK
dc.contributor.authorStanbridge, EJen_HK
dc.contributor.authorLung, MLen_HK
dc.date.accessioned2011-06-17T09:19:16Z-
dc.date.available2011-06-17T09:19:16Z-
dc.date.issued2012en_HK
dc.identifier.citationOncogene, 2012, v. 31 n. 6, p. 728-738en_HK
dc.identifier.issn0950-9232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/134395-
dc.description.abstractFibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved.en_HK
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/oncen_HK
dc.relation.ispartofOncogeneen_HK
dc.subjectanti-angiogenicen_HK
dc.subjectfibulin-2en_HK
dc.subjectmethylationen_HK
dc.subjectnasopharyngeal carcinomaen_HK
dc.subjecttumor suppressoren_HK
dc.subjectVEGFen_HK
dc.titleAnti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0950-9232&volume=in press&spage=&epage=&date=2011&atitle=Anti-angiogenic+And+Tumor-suppressive+Roles+Of+Candidate+Tumor+Suppressor+Gene,+Fibulin-2,+In+Nasopharyngeal+Carcinomaen_US
dc.identifier.emailCheung, AKL: arthurhk@hku.hken_HK
dc.identifier.emailLung, HL: hllung2@hku.hken_HK
dc.identifier.emailCheng, Y: yuecheng@hku.hken_HK
dc.identifier.emailChua, D: dttchua@hkucc.hku.hken_HK
dc.identifier.emailLaiWan Kwong, D: dlwkwong@hku.hken_HK
dc.identifier.emailTsao, SW: gswtsao@hkucc.hku.hken_HK
dc.identifier.emailLung, ML: mlilung@hku.hken_HK
dc.identifier.authorityCheung, AKL=rp01769en_HK
dc.identifier.authorityLung, HL=rp00299en_HK
dc.identifier.authorityCheng, Y=rp01320en_HK
dc.identifier.authorityChua, D=rp00415en_HK
dc.identifier.authorityLaiWan Kwong, D=rp00414en_HK
dc.identifier.authorityTsao, SW=rp00399en_HK
dc.identifier.authorityLung, ML=rp00300en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/onc.2011.272en_HK
dc.identifier.pmid21743496en_HK
dc.identifier.scopuseid_2-s2.0-84856949774en_HK
dc.identifier.hkuros185871en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84856949774&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume31en_HK
dc.identifier.issue6en_HK
dc.identifier.spage728en_HK
dc.identifier.epage738en_HK
dc.identifier.eissn1476-5594-
dc.identifier.isiWOS:000300222100006-
dc.publisher.placeUnited Kingdomen_HK
dc.relation.projectCentre for Nasopharyngeal Carcinoma Research-
dc.identifier.scopusauthoridLaw, EWL=36742183700en_HK
dc.identifier.scopusauthoridCheung, AKL=8967932600en_HK
dc.identifier.scopusauthoridKashuba, VI=34770221200en_HK
dc.identifier.scopusauthoridPavlova, TV=35314397400en_HK
dc.identifier.scopusauthoridZabarovsky, ER=7007009108en_HK
dc.identifier.scopusauthoridLung, HL=6603819904en_HK
dc.identifier.scopusauthoridCheng, Y=36131038300en_HK
dc.identifier.scopusauthoridChua, D=7006773480en_HK
dc.identifier.scopusauthoridLaiWan Kwong, D=15744231600en_HK
dc.identifier.scopusauthoridTsao, SW=7102813116en_HK
dc.identifier.scopusauthoridSasaki, T=7407396809en_HK
dc.identifier.scopusauthoridStanbridge, EJ=7103249410en_HK
dc.identifier.scopusauthoridLung, ML=7006411788en_HK
dc.identifier.citeulike9543910-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats